NGVTIngevity Corporation

$69.86+24% 1Y

Is it growing?

Mixed

Neither accelerating nor breaking down: nothing decisive, though earnings down −125% year on year.

1 to watch, 1 neutral, 1 without data
Revenue trend−1% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: −3% a year.

Earnings trend−125% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearsbottom 1% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is NGVT growing?

Ingevity Corporation has grown revenue −13% a year over three years and −2.8% a year over five, with earnings per share compounding at −32%.

−13%

Revenue growth, 3-year annual rate · Specialty Chemicals median +3.3% · shrinking · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate
−2.8%

Revenue growth, 5-year rate · −13% over three · growth has slowed since the five-year average

Earnings per share, 3-year rate
−32%

Earnings per share, 3-year rate · revenue −13% · earnings lagged revenue: the growth is costing something

Years of annual history on file
12

Years of annual history on file · FY2014 to FY2025, as filed

Details›
Revenue FY2021
$1.39B
Revenue FY2022
$1.67B
Revenue FY2023
$1.22B
Revenue FY2024
$1.20B
Revenue FY2025
$1.17B

Annual income statements as filed with the SEC.